Tantawy R et al., 2026-10: Oral squamous cell carcinoma cell study finding that adding ivermectin to cisplatin was antagonistic, reducing cytotoxicity versus cisplatin alone, attenuating cisplatin-induced S-phase arrest and lowering pro-apoptotic BAX and caspase-3 expression.
Contrary to expectations, the CIS-IVM combination demonstrated an antagonistic interaction in HN9 cells.
n/a (HTML full text)
Tantawy R et al., 2026-10: Oral squamous cell carcinoma cell study finding that adding ivermectin to cisplatin was antagonistic, reducing cytotoxicity versus cisplatin alone, attenuating cisplatin-induced S-phase arrest and lowering pro-apoptotic BAX and caspase-3 expression. Study type: HN9 oral squamous carcinoma cells with OEC normal epithelial cells as control, in vitro. N: n/a. Country: Egypt (authors' affiliations per article). Dose: not stated in the abstract. Declared COI: 'The authors declare no competing interests.' The paper also discloses AI assistance in Introduction and Discussion. Comparator: cisplatin monotherapy. Directly contradicts the assumption that ivermectin adds to standard chemotherapy. Study type: lab.
